GRAYZEL DAVID S.
SEC CIK 1732786 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | Dir | 14.5K | $7.50M | $334.5K | 3 | 2021-07-02 | 2024-04-09 |
Most active insiders at JBIO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Balta Elizabeth | See Remarks | — | — |
| 2 | Frohlich Tom | CEO, Dir | — | — |
| 3 | King Andrew James | See Remarks | — | — |
| 4 | Dahms Bradford D. | CFO | — | — |
| 5 | Fairmount Healthcare Fund II L.P. | Dir, 10% | — | — |
GRAYZEL DAVID S. made no open-market trades at JBIO in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-04-11 | 2024-04-09 | JBIO | Jade Biosciences, Inc. | GRAYZEL DAVID S. | Dir | S - Sale | $28.15 | -11.9K | 14.5K | -45% | -$334.5K |
| DI | 2021-07-06 | 2021-07-02 | JBIO | Jade Biosciences, Inc. | GRAYZEL DAVID S. | Dir | C - Cnv Deriv | — | +2.57M | 2.57M | New | — |
| DI | 2021-07-06 | 2021-07-02 | JBIO | Jade Biosciences, Inc. | GRAYZEL DAVID S. | Dir | P - Purchase | $14.00 | +535.7K | 3.10M | +21% | +$7.50M |
Purchase Sale Sale after option exercise All abbreviations